Spermatogenic stage sensitivity to 6-mercaptopurine in the mouse.
Hybrid (101 X C3H)F1 male mice were given [3H]thymidine intraperitoneally, and 1 h later 150 mg/kg 6-mercaptopurine in 0.03 N NaOH. Autoradiography of testis sections showed that the rate of spermatogenesis was not altered, and the time of appearance of labeled spermatozoa in the ejaculate indicated that 6-mercaptopurine also had no effect on minimum sperm transport time. Labeled spermatozoa persisted in the ejaculate for a longer interval in 6-mercaptopurine-treated males than in controls, most likely as a result of oligospermia. Combined treatment with 150 R X-rays and 150 mg/kg 6-mercaptopurine gave an additive effect and demonstrated conclusively that the peak incidence of dead implants observed at 30.5 - 35.5 days can be attributed to cells treated as preleptotene spermatocytes and must result from genetic damage that is not cytologically detectable; previous work has shown that chromatic and isochromatid breaks at diakinesis-metaphase I occurred only on days 14 and 15 after 150 mg/kg 6-mercaptopurine. From the present experiments it is clear that these aberrations are not related to the dominant lethality at 30.5 - 35.5 days.
D000818:Animals; D002453:Cell Cycle; D002470:Cell Survival; D002869:Chromosome Aberrations; D005260:Female; D005313:Fetal Death / Q000209:etiology; D008297:Male; D015122:Mercaptopurine / Q000494:pharmacology*; D051379:Mice; D009845:Oligospermia / Q000139:chemically induced; D011247:Pregnancy; D013090:Spermatocytes / Q000187:drug effects* / Q000528:radiation effects; D013091:Spermatogenesis / Q000187:drug effects* / Q000528:radiation effects; D013094:Spermatozoa / Q000187:drug effects*; D013997:Time Factors
D015122:Mercaptopurine